Vatiquinone (PTC743)
Small molecule
Also known as EPI-743, PTC725
Evidence outlook · regulatory review
Friedreich Ataxia: FDA issued a complete response letter (2025-08-19)
FDA issues complete response letter for the vatiquinone NDA in Friedreich's ataxia. A complete response letter means the application was not approved as filed; the sponsor may resubmit. The event is listed under Regulatory events.
Latest reported trial: MOVE-FA (NCT04577352) · Phase 2/3 · missed primary endpoint · grade pending
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
MOVE-FA NCT04577352 · Friedreich Ataxia MOVE-FA randomized patients aged 7 to 21 years with Friedreich ataxia to vatiquinone or placebo for 72 weeks under quadruple masking. The primary endpoint was the change in the modified Friedreich Ataxia Rating Scale (mFARS) score at Week 72, registered in two analysis populations. Disease progression was numerically smaller with vatiquinone, but the difference from placebo was not statistically significant in either population (p=0.144 and p=0.098), so the primary endpoint was missed. Source: the CT.gov posted results. Registry: NCT04577352 | 2/3 | Change From Baseline in the mFARS Score at Week 72 - Modified Intent-to-treat (mITT) Analysis Set (Baseline, Week 72); Change From Baseline in the mFARS Score at Week 72 - Intent-to-treat (ITT) Analysis Set (Baseline, Week 72) 2023-04-04 | Change from baseline in mFARS score at Week 72 (two registered primaries, the same endpoint in two analysis sets), vatiquinone vs placebo: mITT (61 vs 62) LS mean +1.218 vs +2.828, difference -1.610 (95% CI -3.769 to 0.550), p=0.144; ITT (70 vs 73) LS mean +0.898 vs +2.555, difference -1.657 (95% CI -3.622 to 0.308), p=0.0984 (CT.gov posted results). | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (3)
What this study did
What this study did
What this study did
Phase 2/3 (2)
What this study did
What this study did
Phase 2 (11)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1/2 (1)
What this study did
Phase 1 (1)
What this study did
Competitive landscape
No competitors sharing a mechanism or indication in the current universe.
Upcoming events
(2 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Vatiquinone (PTC743) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
Regulatory and conference events
(4)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent